Filing Flows › Health Care › OSR Health (OSRH)
OSR Health (OSRH) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · OSR Health (OSRH) Q2 2026 earnings results →
Q2 2026 Revenue down 72% year over year to $316K · 318¢ of every $1 of revenue lost · operating margin -960.8%
OSR Health made $316K in Q2 2026 (-72% Y/Y). Operating margin -960.8%, net loss $1.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $316K in Q2 2026, down 72% year over year and down 35% from the previous quarter.
Gross margin was 27.4%, up 24.5 points from Q2 2025. Operating costs exceeded revenue by $3.0M, an operating margin of -960.8%. Operating expenses fell 41% while revenue fell 72%. The quarter ended with a net loss of $1.0M, narrower than the previous quarter's $3.5M loss. Minority interests bore $155K of it: to shareholders the quarter was a loss of $849K. Non-operating items added $1.6M, -110% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$2.4M. Non-cash charges added back $2.4M of depreciation and amortization. Working capital and other items used $3.8M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $316K | -72% | -960.8% | −$1.0M | −$2.4M |
| Q1 2026 | 10-Q | May 13, 2026 | $484K | -36% | -757.6% | −$3.5M | −$1.0M |
| Q4 2025 | 10-K | Mar 31, 2026 | $381K | -58% | n/m | −$7.2M | −$1.1M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $628K | -24% | -605.9% | −$3.2M | −$2.7M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.1M | +29% | -460.5% | −$5.2M | −$483K |
| Q1 2025 | 10-Q | May 20, 2025 | $761K | -16% | -383.3% | −$11.4M | −$64K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
About OSR Health
As a global healthcare holding company, with operations in South Korea and Switzerland and an office in the United States, we intend to leverage our existing and expanding network of academic and industry leaders and investor network, including venture capital and private equity, in major healthcare markets globally to identify, lead and support the growth of our subsidiaries and subsidiary candidates based on innovative research. Subsidiary candidates are companies that are either already existing entities or new companies formed in connection with acquiring or licensing existing assets from industry or academia. We expect to attract industry partners either as co-investors or through technology licensing deals and may raise capital directly from private, strategic or public investors.
In its own words, from its 10-K, filed Mar 31, 2026.
OSR Health against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -72% against the peers' median +5%. Operating margin: -960.8% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| OSRH OSR Health | Q2 2026 | $316K | -72% | -960.8% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: OSR Health 10-Q on SEC EDGAR · CIK 1840425 · Surgical & Medical Instruments & Apparatus
13F: who owns OSRH and who is buying
More on OSRH
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results